GlassScriptPhysician profile
Chad Shaykher
NPI 1619975893
$869.80
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $234 · 2021: $235 · 2022: $174.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $256.01 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.64 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $106.53 | 2020-2021 | |
| Pfizer INC. | $100.01 | 2019-2022 | |
| Boston Scientific Corporation | $71.14 | 2022 | |
| Akcea Therapeutics, INC. | $60.17 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.53 | 2021 | |
| Amgen INC. | $25.29 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.51 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.99 | 2019 | |
| Astellas Pharma US INC | $14.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Shaykher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.